



MURDOCH
UNIVERSITY
PERTH, WESTERN AUSTRALIA

**FLJ22318: A Novel Binding Partner of the NKX3-1
Homeodomain Protein in Prostate Cancer Cells**

Linda Fiona Dawson

B.Sc. (Hons)

**This thesis is presented for the degree of Doctor of Philosophy
of Murdoch University, October 2006**

School of Biological Sciences & Biotechnology, Murdoch University,
Perth, Western Australia

I declare that this thesis is my own account of my research and contains as its main content work which has not previously been submitted for a degree at any tertiary education institution.

.....

Linda Fiona Dawson

Thesis Summary

Prostate cancer is a frequently diagnosed malignancy which ranges from an indolent asymptomatic tumour to an aggressive, rapidly lethal systemic disease. Determination of chromosomal, genetic and epigenetic alterations associated with prostate carcinogenesis have led to the characterisation of functional consequences of these alterations, thereby elucidating pathways contributing to malignant growth that can be utilised clinically and therapeutically.

FLJ22318 is a novel hypothetical protein that was identified by yeast two-hybrid analysis to interact with the prostatic homeodomain protein, NKX3-1. Expression of NKX3-1 is largely restricted to epithelial cells of the adult prostate where it is involved in maintaining the prostatic phenotype, while NKX3-1 expression is reduced or absent in prostate tumours. In contrast, FLJ22318 expression is documented in cDNA libraries derived from a variety of human adult and foetal tissues including the prostate, suggesting that it may be ubiquitously expressed and that it potentially interacts with a number of proteins in addition to NKX3-1. FLJ22318 expression is undocumented in human prostate tumours.

Bioinformatic analyses have postulated multiple FLJ22318 mRNA transcripts however the proposed open reading frames encoded by these transcripts predict the FLJ22318 protein to contain three strong protein-protein interaction domains, a Lissencephaly type-1-like homology (LisH), a C-terminal to LisH (CTLH) and a CT11-RanBPM (CRA) domain. Of the 44 single nucleotide polymorphisms identified within the *FLJ22318* gene, none are located within the protein coding region suggesting that FLJ22318 may be critical for cell survival and/or function. Comparison of the amino acid sequence between human FLJ22318 and its orthologues in a diverse range of mammalian species identified >97% sequence homology, providing further strong evidence of the critical cellular function of FLJ22318.

To characterise the biological activity of FLJ22318 in prostate cancer cells, the FLJ22318 coding region was amplified by polymerase chain reaction (PCR) and ligated into mammalian and bacterial expression vectors to encode V5-, myc-, GFP-, HA-, and

GST-FLJ22318 fusion proteins. Interaction between FLJ22318 and NKX3-1 was confirmed using (reverse) yeast two-hybrid, GST pull-down and co-immunoprecipitation assays. These data were supported by confocal microscopy which demonstrated the perinuclear and nuclear co-localisation of FLJ22318 and NKX3-1 in prostate cancer cells. Northern blotting identified expression of ~2Kb and ~4Kb FLJ22318 mRNA's in prostate cancer cell lines, which was consistent with bioinformatic analyses of mRNA species. Transfection of prostate cancer cells to overexpress FLJ22318 did not alter endogenous NKX3-1 levels, however FLJ22318 exhibited transcriptional repressor function on an NKX3-1 responsive element and increased NKX3-1 transcriptional repressor activity on this element.

To further investigate FLJ22318 function, additional yeast two-hybrid analyses were performed in prostate cancer cells to identify potential FLJ22318 binding proteins. These studies isolated cDNA's encoding 33 different proteins involved in cell metabolism and apoptosis as well as transcriptional regulators associated with control of cellular proliferation. One of the candidate FLJ22318 interactors, protein kinase, interferon-inducible double stranded RNA dependent activator (PRKRA/PACT) was shown using confocal microscopy to extensively co-localise with FLJ22318 in the cytoplasm and perinuclear regions of prostate cancer cells. Preliminary co-immunoprecipitation and GST pull-down assays have provided additional evidence of the interaction of PRKRA and FLJ22318.

Results of this thesis have generated important information characterising the structure of the FLJ22318 gene and protein, the interaction between FLJ22318 and NKX3-1 and the potential functions of FLJ22318 in prostate cancer cells. As the FLJ22318 gene is located on 5q35, a chromosomal region frequently disrupted in a variety of tumours, future studies of the biological activity of FLJ22318 will clarify its normal cellular functions and its contribution to tumorigenesis or malignant progression in the prostate and in other tissues.

Table of Contents

Declaration	i
Thesis Summary	ii
Table of Contents	iv
Acknowledgments	xi
Awards	xii
Publications	xiii
Index to Figures	xv
Index to Tables	xix
Abbreviations	xx
Chapter One – Introduction	
1.1 The Prostate Gland	1
1.1.1 Anatomical Location and Development	1
1.2 Prostate Cancer	6
1.2.1 Prostate Cancer Incidence	6
1.2.2 Aetiology	9
1.2.3 Detection and Diagnosis	11
1.2.4 Grading and Staging	13
1.2.5 Treatment Options and Prognosis	13
1.2.6 Androgen Deprivation and Hormonal Therapies	15
1.2.7 Androgen Independent Prostate Cancer	19
1.2.8 Chromosomal Anomalies in Prostate Cancer	20
1.3 NKX3-1	22
1.3.1 Homeobox Genes	22
1.3.1.1 Homeodomain Proteins	22
1.3.2 NK Homeobox Genes	24
1.3.2.1 NK Homeodomain Proteins	26
1.3.3 The NKX3-1 Homeodomain Protein	29
1.3.3.1 The <i>NKX3-1</i> Gene	29
1.3.3.2 <i>Nkx3-1</i> Expression During Embryogenesis	32
1.3.3.3 <i>Nkx3-1</i> Knockout Mice	33
1.3.3.4 Regulation of NKX3-1 Expression	35

1.3.3.5	NKX3-1 DNA-binding Sites	39
1.3.3.6	NKX3-1 Co-factors	39
1.3.3.7	Isolation of NKX3-1 Co-factors	41
1.4	Summary and Statement of Aims	42

Chapter Two – Materials

2.1	Reagents	43
2.1.1	Primers	43
2.1.2	PCR	43
2.1.3	Plasmids	44
2.1.4	Yeast Assays	45
2.1.5	Tissue Culture	45
2.1.6	Western Blotting	45
2.1.7	Immunocytochemistry	46
2.1.8	Immunoprecipitation	46
2.1.9	Confocal	47
2.1.10	RNA Extraction and Northern Blotting	47
2.1.11	General Reagents	47
2.2	Commercial Kits	49
2.3	Equipment	52

Chapter Three – Methods

3.1	Polymerase Chain Reaction (PCR)	55
3.1.1	Primer Design	55
3.1.2	Reverse Transcription (RT)	55
3.1.3	Polymerase Chain Reaction	56
3.1.4	Agarose Gel Electrophoresis	56
3.1.5	Purification of PCR Products and Plasmids	56
3.1.6	Gel Purification of DNA	58
3.2	Cloning of FLJ22318	58
3.2.1	Plasmid Vectors	58
3.2.2	Restriction Enzyme Digestion	65
3.2.3	Calf Intestinal Alkaline Phosphatase Treatment	65

3.2.4	Ligation of PCR Products into Plasmid Vectors	65
3.2.5	Preparation of Competent Bacterial Cells	68
3.2.6	Bacterial Transformation	69
3.2.7	Preparation of Bacterial/Glycerol Stocks	70
3.3	Plasmid Purification	70
3.3.1	Small-Scale Isolation of Plasmid DNA	70
3.3.2	Large-Scale Isolation of Plasmid DNA	71
3.3.3	Spectrophotometric Quantitation of DNA/RNA	72
3.4	DNA Sequencing	72
3.4.1	Sequencing Reactions	72
3.4.2	Precipitation of Sequencing Reactions	72
3.5	Yeast Two-hybrid Analysis	73
3.5.1	Polyadenylated RNA Extraction and cDNA Synthesis	73
3.5.1.1	Polyadenylated RNA Extraction	73
3.5.1.2	First-Strand cDNA Synthesis	75
3.5.2	cDNA Library Construction	75
3.5.2.1	Long Distance-PCR (LD-PCR)	75
3.5.2.2	LD-PCR Product Purification	75
3.5.3	Preparation of Competent Yeast Cells	76
3.5.4	Small Scale LiAc Yeast Transformation	77
3.5.5	Large Scale LiAc Yeast Transformation	77
3.5.6	Library Scale LiAc Yeast Transformation	78
3.5.7	Preparation of Yeast/Glycerol Stocks	78
3.5.8	Plasmid Isolation from Yeast	79
3.5.9	Transcriptional Activation of DNA-BD Fusion Construct	79
3.5.10	Toxicity of DNA-BD Fusion Construct	79
3.5.11	Preparation of Yeast Protein Extracts	80
3.6	Tissue Culture	80
3.6.1	Cell Culture Conditions	80
3.6.2	Transfection of Cells	81
3.6.3	Cryopreservation of Cell Cultures	81
3.6.4	DHT Treatment of Cells	83
3.7	Western Blotting	83

3.7.1	Protein Extraction	83
3.7.2	Polyacrylamide Gel Electrophoresis	83
3.7.3	Western Transfer	84
3.7.4	Western Blotting	84
3.8	GST Pull-Down Assays	85
3.8.1	Small-Scale Production of GST Fusion Proteins	85
3.8.2	Coomassie Blue Staining of Gels	86
3.8.3	Large-Scale Production and Purification of GST Fusion Proteins	86
3.8.4	GST Pull-Down Assays	87
3.9	Immunocytochemistry	88
3.9.1	Slide Preparation	88
3.9.2	Immunocytochemistry	88
3.10	Immunoprecipitation Assays	89
3.11	Confocal Microscopy	90
3.11.1	Immunofluorescence	90
3.11.2	Confocal Microscopy	91
3.12	Luciferase Reporter Assays	92
3.13	Northern Blotting	92
3.13.1	RNA Extraction	92
3.13.2	RNA Gel Electrophoresis	94
3.13.3	Northern Transfer	94
3.13.4	Labelling of DNA Probes	94
3.13.5	Northern Hybridisation	95

Chapter Four – Bioinformatic Analysis of FLJ22318

4.1	Introduction	96
4.2	Results	103
4.2.1	<i>FLJ22318</i> Gene Structure	103
4.2.1.1	Mammalian Gene Homologues of <i>FLJ22318</i>	104
4.2.1.2	Transcriptional Regulation of <i>FLJ22318</i> Expression	112
4.2.1.3	<i>FLJ22318</i> Single Nucleotide Polymorphisms	116
4.2.2	<i>FLJ22318</i> Protein Structure and Homology	116
4.3	Discussion	121

Chapter Five – Characterisation of FLJ22318 Interaction with NKX3-1

5.1	Introduction	133
5.2	Results	136
5.2.1	Construction of FLJ22318 Expression Vectors	136
5.2.1.1	Construction of the FLJ22318-pcDNA3.1/V5-His-TOPO Vector	136
5.2.1.1.1	PCR Optimisation with <i>Taq</i> Polymerase	136
5.2.1.1.2	Cloning of FLJ22318 into pcDNA3.1/V5-His-Topo	138
5.2.1.2	Construction of the pGEX2TK-FLJ22318 Vector	142
5.2.1.2.1	PCR Optimisation with <i>Taq</i> Polymerase	142
5.2.1.2.2	Preparation of pGEX2TK Vector	142
5.2.1.2.3	Cloning of FLJ22318 into pGEX2TK	142
5.2.1.3	Construction of the pGBKT7-FLJ22318 Bait Vector	147
5.2.1.3.1	PCR Optimisation with <i>Pfu</i> Polymerase	147
5.2.1.3.2	Preparation of pGBKT7 Vector	147
5.2.1.3.3	Cloning of FLJ22318 into pGBKT7	149
5.2.1.4	Construction of the pCMV-Myc-FLJ22318 Vector	152
5.2.1.4.1	PCR Optimisation with <i>Pfu</i> Polymerase	152
5.2.1.4.2	Preparation of the pCMV-Myc Vector	154
5.2.1.4.3	Cloning of FLJ22318 into pCMV-Myc	154
5.2.1.5	Construction of the pCMV-HA-FLJ22318 Vector	156
5.2.1.5.1	Preparation of the pCMV-HA Vector	156
5.2.1.5.2	Cloning of FLJ22318 into pCMV-HA	158
5.2.1.6	Construction of the pEGFP-C2-FLJ22318 Vector	158
5.2.1.6.1	Preparation of pEGFP-C2 Vector	158
5.2.1.6.2	Cloning of FLJ22318 into pEGFP-C2	161
5.2.2	Reverse Yeast Two-Hybrid Analysis	161
5.2.2.1	pGBKT7-FLJ22318 Protein Expression	162
5.2.2.2	Transcriptional Activation of pGBKT7-FLJ22318	162
5.2.2.3	Toxicity of pGBKT7-FLJ22318	164
5.2.2.4	Reverse Yeast Two-Hybrid Analysis	164
5.2.3	GST Pull-Down Analysis	167
5.2.3.1	pGEX2TK-FLJ22318 Protein Expression	167
5.2.3.2	Production and Purification of GST-FLJ22318 Fusion Protein	167

5.2.3.3	GST Pull-Down Assay	169
5.2.4	Co-immunoprecipitation of FLJ22318 and NKX3-1	169
5.2.4.1	Co-immunoprecipitation of FLJ22318-pcDNA3.1/V5 and NKX3-1	169
5.2.4.2	Co-immunoprecipitation of pCMV-Myc-FLJ22318 and NKX3-1	170
5.2.4.3	Co-immunoprecipitation of pCMV-HA-FLJ22318 and NKX3-1	173
5.2.4.4	Co-immunoprecipitation of pEGFP-C2-FLJ22318 and NKX3-1	173
5.2.5	Characterisation of <i>FLJ22318</i> Expression	173
5.2.5.1	Preparation of cDNA Probes	173
5.2.5.1.1	Preparation of the FLJ22318 cDNA Probe	173
5.2.5.1.2	Preparation of the GAPDH cDNA Probe	175
5.2.5.2	<i>FLJ22318</i> Expression in Prostate and Breast Cancer Cells	175
5.2.5.3	Androgen Regulation of <i>FLJ22318</i> Expression	177
5.2.6	Cellular Localisation and Co-localisation of FLJ22318 and NKX3-1	177
5.2.7	Transcriptional Activity of FLJ22318	184
5.2.8	Effect of FLJ22318 on NKX3-1 Protein Levels	185
5.3	Discussion	188

Chapter Six – Isolation of FLJ22318 Binding Partners

6.1	Introduction	197
6.1.1	Isolation of FLJ22318 Binding Partners	197
6.1.2	Yeast Two-Hybrid Analysis	199
6.1.3	The pGBKT7 GAL4 DNA-BD Expression Plasmid	202
6.1.4	AH109 Yeast Strain	202
6.1.5	Construction of the cDNA Library	203
6.1.6	pGADT7-Rec GAL4 AD Expression Plasmid and Library Screening	203
6.2	Results	206
6.2.1	Yeast Two-Hybrid Analysis (I)	206
6.2.1.1	RNA Isolation and cDNA Synthesis	206
6.2.1.2	Yeast Two-Hybrid Analysis	208
6.2.2	Yeast Two-Hybrid Analysis (II)	211
6.2.2.1	RNA Isolation and cDNA Synthesis	211
6.2.2.2	Yeast Two-Hybrid Analysis	211

6.2.2.3	Yeast Two-Hybrid Analysis Controls	220
6.3	Discussion	222
Chapter Seven – Analysis of PRKRA: A Candidate FLJ22318 Binding Partner		
7.1	Introduction	228
7.2	Results	230
7.2.1	PRKRA Protein Expression in LNCaP Prostate Cancer Cells	230
7.2.2	Cellular Localisation and Co-Localisation of PRKRA and FLJ22318	232
7.2.3	GST Pull-Down Analysis	235
7.2.4	Co-immunoprecipitation of FLJ22318-pcDNA3.1/V5 and PRKRA	239
7.3	Discussion	240
Chapter Eight – General Discussion		
8.1	Discussion	246
8.2	Future Directions	251
8.3	Concluding Remarks	256
	References	257
	Appendices	285
	Appendix 1 – Buffers and Solutions	285
	Appendix 2 – Primers	302

Acknowledgments

I wish to thank and acknowledge all those who have given me their encouragement, support and assistance in helping me to complete my PhD. In particular, I would like to thank my supervisor Dr. Jacky Bentel, whose continuous support, belief and patience with me has made this possible. I would also like to extend my appreciation to Bob Mead at Murdoch for his support and to my lab buddies Marc, Diana, Darren, Ben and Priscilla for giving me lots of valuable advice, ideas and discussions on my project. More importantly I would like to thank them and all the other people who make up the Anatomical Pathology department at Royal Perth Hospital for making me feel welcome and for their friendship over the years.

Finally, a very special thank-you goes to my family, my children Andrew, Shane, Kaye and Mark and to my husband Neal, whose emotional and mental support and confidence in my abilities has given me the courage to reach and attain this goal, I could not have done this without you all.

Awards

During my PhD studies I have been the recipient of a Murdoch University Research Studentship and an Australian Postgraduate Award.

I was the recipient of the Scientific Section – Encouragement Award for my presentation “FLJ22318: A Novel Co-factor of NKX3.1” at The Merck Sharp & Dohme Young Investigators Meeting in September, 2004.

Publications

Abstracts

Fiona Baxter, **Linda Lawford**, Myles Hodgson, Jacqueline Bentel (2002) Identification of Novel Cofactors of the Prostate Specific Homeodomain Protein NKX3.1. 7th World Congress on Advances in Oncology / 5th International Symposium on Molecular Medicine, Crete, October, 2002 (poster presentation)

Linda Lawford, Fiona Baxter, Robert Mead, Jacqueline Bentel (2003) Characterisation of FLJ22318: A Novel NKX3.1 Binding Protein. Combined Biological Science Meeting (CBSM), Perth, August 2003 (poster presentation)

Linda Lawford, Fiona Baxter, Jacqueline Bentel (2003) Characterisation of FLJ22318, a Novel Co-factor of NKX3.1. Australian Society for Medical Research (ASMR) annual conference, Adelaide, November 2003 (poster presentation)

Linda Dawson, Fiona Baxter, Jacqueline Bentel (2004) FLJ22318: A Novel NKX3.1 Binding Protein. Australian Society for Medical Research (ASMR) Perth, June 2004 (oral presentation)

Linda Dawson, Fiona Baxter, Jacqueline Bentel (2004) FLJ22318: A Novel Co-factor of NKX3.1. The Merck Sharp & Dome 2004 Young Investigators Meeting, Perth, September 2004 (oral presentation)

Linda Dawson, Fiona Baxter, Jacqueline Bentel (2005) Characterisation of a novel protein FLJ22318 in prostate cancer cells. Australian Society for Medical Research (ASMR) Perth, June 2005 (oral presentation)

Linda Dawson, Fiona Baxter, Jacqueline Bentel (2005) Characterisation of FLJ22318 in Prostate Cancer Cells. Combined Biological Science Meeting (CBSM), Perth, August 2005 (poster presentation)

Linda Dawson, Fiona Baxter, Jacqueline Bentel (2005) Characterisation of FLJ22318 in Prostate Cancer Cells. The Endocrine Society of Australia, 48th Annual Scientific Meeting Perth, September 2005 (oral presentation)

Jacqueline Bentel, **Linda Dawson**, Fiona Baxter (2005) FLJ22318, a novel binding partner of the prostate cancer tumour suppressor, NKX3.1. 5th State Cancer Conference / The Cancer Council Western Australia Perth, October 2005 (oral presentation)

Linda Dawson, Jacqueline Bentel (2005) Characterisation of FLJ22318: A novel NKX3.1 binding protein in prostate cancer cells. The Merck Sharp & Dome 2005 Young Investigators Meeting, Perth, November 2005 (oral presentation)

Linda Dawson, Jacqueline Bentel (2006) Characterisation of FLJ22318: A novel NKX3-1 binding partner in prostate cancer cells. Australian Society for Medical Research (ASMR) Perth, June 2006 (oral presentation)

Linda Dawson, Jacqueline Bentel (2006) Characterisation of a novel protein FLJ22318 in prostate cancer cells. Combined Biological Science Meeting (CBSM), Perth, August 2006 (oral presentation)

Index to Figures

Figure	Page
Chapter One – Introduction	
1.1 Anatomical location of the prostate gland	2
1.2 Schematic representation of epithelial cell differentiation in the human prostate	3
1.3 The three distinct morphological regions of the adult human prostate	5
1.4 Age-specific incidence and mortality rates for cancer of the prostate in Australian men for 2001	8
1.5 Age-standardised trend of the incidence and mortality rate for prostate cancer in Australian men from 1983 to 2002	8
1.6 Schematic representation of the binding mode of the homeodomain	23
1.7 Comparison of the proposed ancestral NK cluster to the NK homeobox gene cluster of <i>Homo sapiens</i>	27
1.8 <i>NKX3-1</i> maps to 8p21.2 and spans 4223 base pairs (bp) of genomic DNA	30
1.9 Sequence alignments of mammalian NKX3-1 proteins	31
Chapter Three – Methods	
3.1 Map of the pCR [®] 2.1 vector showing the multiple cloning site and site of FLJ22318 ligation following TA Cloning [®]	59
3.2 Map of the pcDNA3.1/V5-His-TOPO vector showing the TOPO [®] cloning site where PCR products are inserted	60
3.3 Map of the pCMV-Myc vector showing the multiple cloning site (MCS) and the <i>Sal</i> I FLJ22318 insert position	61
3.4 Map of the pCMV-HA vector showing the <i>Sal</i> I insert position for FLJ22318 within the multiple cloning site (MCS)	62
3.5 Map of the pEGFP-C2 vector showing the multiple cloning site (MCS) and <i>Sal</i> I FLJ22318 insert position	63
3.6 Map of the pGEX-2TK vector showing the multiple cloning site (MCS) and <i>Bam</i> H I FLJ22318 insert position	64
3.7 Map of the pGADT7-Rec vector	66
3.8 Restriction map of the pGBKT7 vector showing the GAL4 DNA-BD, multiple cloning site (MCS) and <i>Sal</i> I FLJ22318 insert position	67
3.9 Map of the pcDNA3.1/V5-His-TOPO/ <i>lacZ</i> vector which constitutively expresses β -galactosidase from the CMV promoter when transfected into mammalian cells	93
3.10 Map of the pRL-SV40 vector	93

Chapter Four – Bioinformatic Analysis of FLJ22318

4.1	CpG island surrounding the FLJ22318 transcription start site	97
4.2	Schematic representation of the two α -helices that form the LisH motif	99
4.3	Genomic organisation of FLJ22318	105
4.4	Proposed alternatively spliced transcripts of FLJ22318	106
4.5	Sequence alignments of mammalian FLJ22318 mRNA	108
4.6	Comparison of genomic nucleotide conservation between mammalian homologues of FLJ22318	113
4.7	Analysis of the chromosomal localisation of FLJ22318 from the human, rat and mouse genomes	114
4.8	Transcription factor binding sites of a region encompassing 1000bp upstream of the <i>FLJ22318</i> gene TSS as well as the putative CpG island	117
4.9	Comparative analysis of the promoters from the human and mouse FLJ22318 genes	118
4.10	Position of single nucleotide polymorphisms (SNPs) associated with the FLJ22318 gene	119
4.11	Domain structure of the FLJ22318 protein	119
4.12	Sequence alignments of mammalian FLJ22318 proteins	123
4.13	Sequence alignments of mammalian FLJ13910 proteins and homology between human FLJ22318 and FLJ13910	125

Chapter Five – Characterisation of FLJ22318 Interaction with NKX3-1

5.1	PCR amplification and ligation of FLJ22318 cDNA into pcDNA3.1/V5-His-TOPO	137
5.2	Cloning of FLJ22318 into pcDNA3.1/V5-His-TOPO	139
5.3	Representative sequence and chromatograph of FLJ22318	140
5.4	Optimisation of PCR conditions for FLJ22318 amplification using <i>Taq</i> polymerase	143
5.5	Construction of pGEX2TK-FLJ22318	144
5.6	Screening of pGEX2TK-FLJ22318 transformants	146
5.7	PCR Optimisation of FLJ22318 amplification using <i>Pfu</i> polymerase and FLJSall sense and anti-sense primers	148
5.8	Construction of the pGBKT7-FLJ22318 bait vector	150
5.9	Screening of pGBKT7-FLJ22318 clones	151
5.10	Identification of pGBKT7 containing a FLJ22318 insert	153
5.11	PCR screen for FLJ22318 in pCR [®] 2.1	155
5.12	Screening of pCMV-Myc-FLJ22318 clones	157
5.13	Screening of pCMV-HA-FLJ22318 clones	159
5.14	Construction of the pEGFP-C2-FLJ22318 vector	160

5.15	Expression of Myc-FLJ22318 in yeast	163
5.16	AH109 <i>S. cerevisiae</i> yeast transformed with pGBKT7-FLJ22318	163
5.17	Investigation of FLJ22318 interaction with NKX3-1 using (reverse) yeast two-hybrid analysis	166
5.18	Confirmation of an interaction between FLJ22318 and NKX3-1 in the original and reverse yeast-two hybrid screen	166
5.19	GST-FLJ22318 pull-down Assay	168
5.20	Immunoprecipitation of FLJ22318-pcDNA3.1/V5-His-TOPO	171
5.21	Co-immunoprecipitation of NKX3-1-V5 and Myc-FLJ22318	172
5.22	FLJ22318 interacts with NKX3-1 <i>in vivo</i>	174
5.23	Construction of the cDNA probes	176
5.24	Expression of <i>FLJ22318</i> in prostate and breast cancer cell lines	176
5.25	Androgen regulation of <i>FLJ22318</i> mRNA in LNCaP cells	178
5.26	FLJ22318 and NKX3-1 localisation and co-localisation in DU145 prostate cancer cells	180
5.27	FLJ22318 and NKX3-1 localisation and co-localisation in LNCaP prostate cancer cells	182
5.28	Transcriptional repressor activity of FLJ22318	186
5.29	Exogenous expression of FLJ22318 does not regulate NKX3-1 protein levels in LNCaP cells	187

Chapter Six – Isolation of FLJ22318 Binding Partners

6.1	The BD Matchmaker™ yeast two-hybrid system	201
6.2	cDNA library construction	204
6.3	Yeast two-hybrid library screen	205
6.4	cDNA synthesis from LNCaP poly A ⁺ mRNA	207
6.5	PCR screen of AD/library inserts from pGADT7-Rec to ascertain insert size and to check for multiple AD/library plasmids in colonies	209
6.6	PCR amplification of LNCaP cDNA using poly A ⁺ RNA for the repeat yeast two-hybrid screen	213
6.7	PCR screen of AD/library inserts from pGADT7-Rec	215
6.8	Vector maps of the Yeast-2 Hybrid control vectors	221

Chapter Seven – Analysis of the Potential FLJ22318 Binding Partner: PRKRA

7.1	Western blot analysis of representative LNCaP prostate cancer cell lysates with anti-PRKRA antibodies to detect expression of endogenous PRKRA	231
7.2	Localisation of PRKRA in LNCaP prostate cancer cells	233

7.3	Cellular localisation of FLJ22318 and PRKRA in LNCaP prostate cancer cells	234
7.4	Co-localisation of FLJ22318 and PRKRA in LNCaP prostate cancer cells	236
7.5	Analysis of FLJ22318 and PRKRA co-localisation in LNCaP prostate cancer cells	237
7.6	GST-FLJ22318 pull-down assay	238
7.7	Co-immunoprecipitation of FLJ22318-V5 and PRKRA	241

Index to Tables

Table	Page
<i>Chapter One – Introduction</i>	
1.1 Chromosomal sites and putative susceptibility genes implicated to be involved in hereditary prostate cancer	10
1.2 TNM classification of prostate cancer	14
1.3 Treatment options for prostate cancer based on disease stage	16
1.4 Hormonal therapy treatment options for prostate cancer	17
1.5 Classification of the homeobox genes	25
1.6 Human orthologues of <i>Drosophila</i> NK-related genes	28
<i>Chapter Three – Methods</i>	
3.1 PCR conditions	57
3.2 Yeast medium for glycerol stock preparation	78
3.3 DU145 and LNCaP cell passage numbers	81
3.4 Transfection details	82
3.5 Primary (1°) and secondary (2°) antibody dilutions	85
3.6 Antibody dilutions for immunoprecipitation assays	90
3.7 Immunofluorescence antibody dilutions	91
<i>Chapter Four – Bioinformatic Analysis of FLJ22318</i>	
4.1 AceView proposed transcript and protein variants of FLJ22318	107
4.2 Comparison of gene structure between FLJ22318 and the rat and mouse homologues demonstrates that the coding exons are completely conserved between species	115
4.3 Proposed mammalian orthologues of <i>S. cerevisiae</i> RMD5	122
<i>Chapter Six – Isolation of FLJ22318 Binding Partners</i>	
6.1 mRNA transcripts identified in the initial yeast two-hybrid screen	212
6.2 mRNA transcripts identified in the second yeast two-hybrid screen	217

Abbreviations

5 α R	<i>5α-reductase inhibitor</i>
aa	<i>amino acids</i>
AD	<i>activation domain</i>
Ade	<i>adenine</i>
AES	<i>amino enhancer of split</i>
AF2	<i>activation function 2</i>
AI	<i>androgen independence</i>
Ald	<i>aldolase</i>
AMV	<i>avian myeloblastosis virus</i>
APS	<i>ammonium persulphate</i>
AR	<i>androgen receptor</i>
ARE	<i>androgen response element</i>
Arg	<i>arginine</i>
AS	<i>antisense</i>
Asn	<i>asparagine</i>
ATP	<i>adenosine 5'-triphosphate disodium salt</i>
BAC	<i>β-actin</i>
BD	<i>binding domain</i>
BLAST	<i>Basic Local Alignment Search Tool</i>
bp	<i>base pairs</i>
BPH	<i>benign prostatic hyperplasia</i>
BSA	<i>bovine serum albumin</i>
C	<i>carboxy</i>
CAB	<i>combined androgen blockade</i>
cDNA	<i>complementary deoxyribonucleic acid</i>
CDS	<i>coding domain sequence</i>
CIAP	<i>calf intestinal alkaline phosphatase</i>
CK	<i>cytokeratin</i>
CK2	<i>casein kinase 2</i>
CMV	<i>cytomegalovirus</i>
CNS	<i>central nervous system</i>

CO ₂	<i>carbon dioxide</i>
CRA	<i>CT11-RanBPM</i>
CS	<i>charcoal stripped</i>
CT	<i>computed tomography</i>
CTLH	<i>C-terminal to lissencephaly type-1-like homology domain</i>
CuSO ₄	<i>copper sulphate</i>
Da	<i>daltons</i>
dATP	<i>deoxyadenine triphosphate</i>
dCTP	<i>deoxycytosine triphosphate</i>
DCX	<i>doublecortin</i>
ddH ₂ O	<i>deionised distilled water</i>
DDO	<i>double dropout</i>
DEPC	<i>diethyl pyrocarbonate</i>
DES	<i>diethylstilbestrol</i>
dGTP	<i>deoxyguanine triphosphate</i>
DHT	<i>5α-dihydrotestosterone</i>
DMF	<i>dimethyl formamide</i>
DMSO	<i>dimethyl sulphoxide</i>
DNA	<i>deoxyribonucleic acid</i>
dNTP	<i>deoxynucleotide triphosphate</i>
DO	<i>dropout</i>
DRE	<i>digital rectal examination</i>
ds	<i>double stranded</i>
dT	<i>deoxythymidine</i>
DTT	<i>dithiothreitol</i>
dTTP	<i>deoxythymidine triphosphate</i>
Dyrk	<i>dual-specificity tyrosine phosphorylation-regulated kinases</i>
ECL	<i>enhanced chemiluminescence</i>
EDTA	<i>ethylenediaminetetra-acetic acid</i>
EHD	<i>extended homeodomain</i>
ER	<i>endoplasmic reticulum</i>
EST	<i>expressed sequence tag</i>
FBPase	<i>fructose-1,6-bisphosphatase</i>

FCS	<i>foetal calf serum</i>
FLJ	<i>full long Japanese</i>
FMR1	<i>fragile X mental retardation 1</i>
FTZ	<i>Fushi tarazu</i>
FTZ-1	<i>Fushi tarazu factor 1</i>
G	<i>gauge</i>
Gal	<i>galactosidase</i>
GFP	<i>green fluorescent protein</i>
GID	<i>glucose induced degradation</i>
GO	<i>gene ontology</i>
GR	<i>glucocorticoid receptor</i>
Gro	<i>groucho</i>
GST	<i>glutathione S-transferase</i>
GTF	<i>general transcription factors</i>
HA	<i>haemagglutinin</i>
HAT	<i>histone acetyl transferase</i>
HB	<i>homeobox</i>
HCl	<i>hydrochloric acid</i>
HD	<i>homeodomain</i>
HDAC	<i>histone deacetylase</i>
HECT	<i>homologous to E6-AP carboxyl terminus</i>
HES	<i>hairy enhancer of split</i>
HIPK	<i>homeodomain interacting protein kinase</i>
His	<i>histidine</i>
HnRNPs	<i>heterogeneous ribonucleoproteins</i>
HNRPAB	<i>heterogenous nuclear ribonucleoprotein A/B</i>
HP	<i>hexapeptide</i>
HPVs	<i>human papillomaviruses</i>
HRP	<i>horseradish peroxidase</i>
Ig	<i>immunoglobulin</i>
IPTG	<i>isopropyl-β-D-thiogalactoside</i>
Kb	<i>kilobase</i>
KCl	<i>potassium chloride</i>

kDa	<i>kilodaltons</i>
LB	<i>Luria Bertani</i>
LBD	<i>ligand binding domain</i>
LD	<i>long distance</i>
Leu	<i>leucine</i>
LH-RH	<i>luteinising hormone-releasing hormone</i>
LiAc	<i>lithium acetate</i>
LisH	<i>lissencephaly type-1-like homology</i>
LOH	<i>loss of heterozygosity</i>
Luc	<i>luciferase</i>
MAEA	<i>macrophage erythroblast attacher</i>
MCS	<i>multiple cloning site</i>
MGC	<i>mammalian gene collection</i>
MgCl ₂	<i>magnesium chloride</i>
MGMT	<i>O⁶-methyl-guanine-DNA methyltransferase</i>
MgSO ₄	<i>magnesium sulphate</i>
MITOP	<i>mitochondrial proteome database</i>
MOPS	<i>3-[N-Morpholino]propanesulphonic acid</i>
MMLV	<i>Moloney Murine Leukaemia Virus</i>
mRNA	<i>messenger ribonucleic acid</i>
MS	<i>mass spectrometry</i>
N	<i>amino</i>
N4BP3	<i>Nedd4 binding protein 3</i>
NaCl	<i>sodium chloride</i>
NaOH	<i>sodium hydroxide</i>
NCBI	<i>National Center for Biotechnology Information</i>
NCI	<i>National Cancer Institute</i>
N-CoR	<i>nuclear receptor co-repressor</i>
NDE1	<i>nuclear distribution gene E homolog 1</i>
NDEL1	<i>NDE1-Like 1</i>
(NH ₄) ₂ SO ₄	<i>ammonium sulphate</i>
NK2-SD	<i>NK2-specific domain</i>
NLS	<i>nuclear localisation signal</i>
NOLA2	<i>nucleolar protein family A member 2</i>

NP-40	<i>nonidet P-40</i>
NPAT	<i>ataxia-telangiectasia locus protein</i>
NRB	<i>nuclear receptor box</i>
OD	<i>optical density</i>
OFD1	<i>oral-facial-digital syndrome type I</i>
OPN	<i>osteopontin</i>
ORC	<i>origin recognition complex</i>
ORF	<i>open reading frame</i>
PAFAH1B1	<i>platelet-activating factor acetylhydrolase, isoform 1b, alpha subunit</i>
PBS	<i>phosphate buffered saline</i>
p.c.	<i>post coitum</i>
PCD	<i>programmed cell death</i>
PCR	<i>polymerase chain reaction</i>
PDEF	<i>prostate derived Ets factor</i>
PEG	<i>polyethylene glycol</i>
PFK	<i>phosphofructokinase</i>
Pfu	<i>Pyrococcus furiosus</i>
Phe	<i>phenylalanine</i>
PIN	<i>prostatic intraepithelial neoplasia</i>
PIPES	<i>piperazine-N,N'-bis (2-ethanesulphonic acid)</i>
PKC	<i>protein kinase C</i>
PLB	<i>passive lysis buffer</i>
PMSF	<i>phenylmethylsulphonylfluoride</i>
P/S	<i>penicillin/streptomycin</i>
PSA	<i>prostate specific antigen</i>
QDO	<i>quadruple dropout</i>
RANBP9	<i>RAN-binding protein 9</i>
RAR	<i>retinoid acid receptor</i>
Rb	<i>retinoblastoma</i>
RING	<i>really interesting new gene</i>
RIPA	<i>radioimmunoprecipitation assay</i>
RNA	<i>ribonucleic acid</i>
rpm	<i>revolutions per minute</i>
rRNA	<i>ribosomal ribonucleic acid</i>

RT	<i>reverse transcription</i>
RXR	<i>retinoid X receptor</i>
S	<i>sense</i>
SAAB	<i>selection and amplification binding assay</i>
SDS	<i>sodium dodecyl sulphate</i>
siRNA	<i>small interfering RNA</i>
SMART	<i>simple modular architecture research tool</i>
SMGA	<i>smooth muscle gamma-actin</i>
SMRT	<i>silencing mediator of retinoid and thyroid hormone receptor</i>
SNP	<i>single nucleotide polymorphism</i>
SRF	<i>serum response factor</i>
ss	<i>single stranded</i>
SSC	<i>sodium chloride, sodium citrate</i>
TAE	<i>TRIS, [ethylenedinitrilo] tetra-acetic acid</i>
Taq	<i>Thermus aquaticus</i>
TBL1X	<i>transducin β-like 1X</i>
TBS	<i>TRIS buffered saline</i>
TBST	<i>TRIS buffered saline/TWEEN 20</i>
TCA	<i>tricarboxylic acid</i>
TGCTs	<i>testicular germ cell tumours</i>
TDO	<i>triple dropout</i>
TE	<i>TRIS/EDTA</i>
TEMED	<i>[N, N, N', N'-Tetra-methyl]-ethylenediamine</i>
TIF	<i>tagged image format</i>
TK	<i>thymidine kinase</i>
TLE	<i>transducin-like enhancer of split</i>
TNM	<i>tumour, node, metastases classification</i>
TR	<i>thyroid receptor</i>
TRIS	<i>tris(hydroxymethylaminomethane)</i>
Triton X-100	<i>Octylphenoxy polyethoxyethanol</i>
Trp	<i>tryptophan</i>
TRUS	<i>transrectal ultrasound</i>
TSG	<i>tumour suppressor gene</i>

TSS	<i>transcription start site</i>
UAS	<i>upstream activating sequence</i>
UTR	<i>untranslated region</i>
UV	<i>ultraviolet</i>
V	<i>volts</i>
WD	<i>tryptophan-asparagine</i>
X-Gal	<i>5-bromo-4 chloro-3-indolyl-β-D-galactopyranoside</i>
X- α -Gal	<i>5-bromo-4 chloro-3-indolyl-α-D-galactopyranoside</i>
Y2H	<i>yeast two-hybrid</i>
YPDA	<i>yeast peptone dextrose agar</i>